A large percentage of patients prescribed the biotech's lone drug stop taking it early. Can two changes to its dosing protocols solve that problem?
News & Analysis: Puma Biotechnology
PBYI earnings call for the period ending September 30, 2019.
Investors are eager to see how Nerlynx is faring in light of a high discontinuation rate among patients and a recent label supplement that could reverse the trend.
These three beaten-down cancer stocks could prove to be amazing value plays.
An analyst downgrade and a departing executive make for a bad day.
PBYI earnings call for the period ending June 30, 2019.
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
The market's shortsightedness has it missing the long-term upside at this biotech, logistics specialist, and pipeline company.
The most significant potential concern for the company's lone drug product arose.
A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.